Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.


Serval ID
Article: article from journal or magazin.
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.
JAMA psychiatry
Jansen W.J., Ossenkoppele R., Tijms B.M., Fagan A.M., Hansson O., Klunk W.E., van der Flier W.M., Villemagne V.L., Frisoni G.B., Fleisher A.S., Lleó A., Mintun M.A., Wallin A., Engelborghs S., Na D.L., Chételat G., Molinuevo J.L., Landau S.M., Mattsson N., Kornhuber J., Sabri O., Rowe C.C., Parnetti L., Popp J., Fladby T., Jagust W.J., Aalten P., Lee D.Y., Vandenberghe R., Resende de Oliveira C., Kapaki E., Froelich L., Ivanoiu A., Gabryelewicz T., Verbeek M.M., Sanchez-Juan P., Hildebrandt H., Camus V., Zboch M., Brooks D.J., Drzezga A., Rinne J.O., Newberg A., de Mendonça A., Sarazin M., Rabinovici G.D., Madsen K., Kramberger M.G., Nordberg A., Mok V., Mroczko B., Wolk D.A., Meyer P.T., Tsolaki M., Scheltens P., Verhey FRJ, Visser P.J., Aarsland D., Alcolea D., Alexander M., Almdahl I.S., Arnold S.E., Baldeiras I., Barthel H., van Berckel BNM, Blennow K., van Buchem M.A., Cavedo E., Chen K., Chipi E., Cohen A.D., Förster S., Fortea J., Frederiksen K.S., Freund-Levi Y., Gkatzima O., Gordon M.F., Grimmer T., Hampel H., Hausner L., Hellwig S., Herukka S.K., Johannsen P., Klimkowicz-Mrowiec A., Köhler S., Koglin N., van Laere K., de Leon M., Lisetti V., Maier W., Marcusson J., Meulenbroek O., Møllergård H.M., Morris J.C., Nordlund A., Novak G.P., Paraskevas G.P., Perera G., Peters O., Ramakers IHGB, Rami L., Rodríguez-Rodríguez E., Roe C.M., Rot U., Rüther E., Santana I., Schröder J., Seo S.W., Soininen H., Spiru L., Stomrud E., Struyfs H., Teunissen C.E., Vos SJB, van Waalwijk van Doorn LJC, Waldemar G., Wallin Å.K., Wiltfang J., Zetterberg H.
Working group(s)
Amyloid Biomarker Study Group
2168-6238 (Electronic)
Publication state
Issued date
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
Publication Status: ppublish
Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.
To investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia.
This cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017.
Global cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype.
Among 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P < .001) and low MMSE (mean difference, 14% [95% CI, 12%-17%], P < .001) scores, and this association decreased with age. Low cognitive scores had limited utility for screening of amyloid positivity in persons with normal cognition and those with MCI. In persons with normal cognition, the age-related increase in low memory score paralleled the age-related increase in amyloid positivity with an intervening period of 10 to 15 years.
Although low memory scores are an early marker of amyloid positivity, their value as a screening measure for early AD among persons without dementia is limited.
Aged, Alzheimer Disease/diagnosis, Alzheimer Disease/physiopathology, Alzheimer Disease/psychology, Amyloid beta-Peptides/cerebrospinal fluid, Brain/physiopathology, Cognition Disorders/diagnosis, Cognition Disorders/physiopathology, Cognition Disorders/psychology, Cognitive Dysfunction/diagnosis, Cognitive Dysfunction/physiopathology, Cognitive Dysfunction/psychology, Cross-Sectional Studies, Female, Humans, Male, Memory, Episodic, Mental Status and Dementia Tests, Middle Aged, Positron-Emission Tomography, Reference Values
Web of science
Create date
09/12/2017 10:40
Last modification date
24/09/2019 6:11
Usage data